Surrey Heartlands

Joint Formulary & PAD

Enoxaparin - VTE prevention post hip/knee replacement

You are here : Home > Formulary Search > Enoxaparin - VTE prevention post hip/knee replacement

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important
Prescribe by brand. RSCH / SASH / ASPH = Inhixa brand

Documentation

Guidelines (Local)
Venous Thromboembolism Prophylaxis - SWLEOC Guidelines - Feb 19
Guidelines (Local)
Inhixa communication to GP practices in East Surrey - Feb 2021
Guidelines (Local)
NWS Enoxaparin Brand switch primary care comms Nov 2024

PAD Profile

ChemicalSubstance :
Enoxaparin
Indication :
VTE prevention post hip/knee replacement
Group Name :
Keywords :
VTE prophylaxis, venous thromboembolism, Low molecular weight heparins, LMWH, SWLEOC guidelines
Brand Names Include :
Clexane, Inhixa, enoxaparin BECAT, Arovi
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Enoxaparin is used to treat.

Other Drugs

Below are listed other drugs that are used to treat VTE prevention post hip/knee replacement.

Committee Recommendations (4)

06 Nov 24 - NW Surrey Medicines Optimisation Group

North West Surrey / ASPH local recommendation:

Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

See the "NWS Enoxaparin brand switch" document for details

23 Feb 21 - East Surrey MOG

East Surrey / SASH local recommendation:

Inhixa is the preferred brand of enoxaparin at Surrey and Sussex Healthcare NHST trust. Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

See Inhixa communication document for GPs below

22 Jan 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

Note; differences in the mechanisms for operation in needle guard between presentations of enoxaparin.
29 Oct 03 - Not Set
The use of LMWH to prevent VTE post operatively is considered as red on the traffic light system. The full course of treatment should be supplied by the Acute Trust.